Differential protein expression in endothelial cells exposed to serum from patients with acute graft-vs-host disease, depending on steroid response.
aGVHD
endothelial damage biomarkers
endothelium
proteomic analysis
steroid-refractory aGVHD
Journal
Journal of cellular and molecular medicine
ISSN: 1582-4934
Titre abrégé: J Cell Mol Med
Pays: England
ID NLM: 101083777
Informations de publication
Date de publication:
05 2023
05 2023
Historique:
revised:
22
02
2023
received:
15
12
2022
accepted:
24
02
2023
medline:
1
5
2023
pubmed:
6
4
2023
entrez:
5
4
2023
Statut:
ppublish
Résumé
Graft-versus-host disease (GVHD) is a complication of allogeneic haematopoietic cell transplantation. Endothelial injury is crucial as pathophysiological substrate for GVHD. GVHD first-line treatment is high-dose corticosteroids, although some patients are steroid-refractory. Through the present study, we compared the endothelial proteomic profiles in response to serum from steroid-refractory acute GVHD (SR-aGVHD) and steroid-sensitive acute GVHD (SS-aGVHD) patients. Blood samples from SR-aGVHD (n = 4) and SS-aGVHD (n = 8) patients were collected at aGVHD diagnosis. Endothelial cell cultures were exposed (48 h) to patients' serum. Protein extraction and proteomic analysis were performed. Differences were statistically evaluated by multivariate analysis. Forty-four proteins contributed to separate all samples into the two study groups, among which 15 participated significantly (p < 0.05), 10 exhibiting a fold change >1.2. Differentially expressed proteins were mainly associated with oxidative phosphorylation (Cytochrome C oxidase subunit 6B1, CX6B1), inflammation and angiogenesis (Apolipoprotein D, APOD), cell survival (Rapamycin-insensitive companion of mTOR, RICTR), and oxidative stress (Riboflavin kinase, RIFK). This pilot study used a novel approach to distinguish the aGVHD response to steroid treatment. The proteins differentially expressed could constitute potential biomarkers for steroid-treatment response. These findings signify a step forward to identify the mechanisms of response to steroids, of high clinical relevance considering the SR-aGVHD elevated mortality.
Identifiants
pubmed: 37016544
doi: 10.1111/jcmm.17712
pmc: PMC10148062
doi:
Substances chimiques
Steroids
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1227-1238Informations de copyright
© 2023 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd.
Références
DNA Repair (Amst). 2014 Nov;23:4-16
pubmed: 24865146
Mech Ageing Dev. 2003 Aug-Sep;124(8-9):911-9
pubmed: 14499496
Cancer Cell. 2006 Aug;10(2):159-70
pubmed: 16904613
Front Cell Dev Biol. 2022 Jan 14;9:801200
pubmed: 35096828
Cancer Control. 2011 Oct;18(4):268-76
pubmed: 21976245
Curr Med Chem. 2009;16(10):1266-77
pubmed: 19355884
Haematologica. 2017 May;102(5):958-966
pubmed: 28302712
Nature. 2009 Aug 27;460(7259):1159-63
pubmed: 19641494
Biol Blood Marrow Transplant. 2009 May;15(5):537-46
pubmed: 19361745
Cell. 2012 Apr 13;149(2):274-93
pubmed: 22500797
Biochem Pharmacol. 2002 Jul 15;64(2):327-37
pubmed: 12123754
Lancet. 2009 May 2;373(9674):1550-61
pubmed: 19282026
Mol Cell Biol. 2000 Jul;20(13):4532-42
pubmed: 10848580
Bone Marrow Transplant. 2010 Feb;45(2):219-34
pubmed: 19584824
J Biol Chem. 2001 Jun 1;276(22):18665-72
pubmed: 11279143
Clin Cancer Res. 2018 Jun 1;24(11):2482-2490
pubmed: 29420223
Annu Rev Med. 2003;54:29-52
pubmed: 12359826
Mol Cell Biol. 2004 May;24(10):4502-12
pubmed: 15121867
Bone Marrow Transplant. 2011 Dec;46(12):1495-502
pubmed: 21460864
Semin Oncol. 2012 Dec;39(6):683-93
pubmed: 23206845
Front Immunol. 2019 Oct 09;10:2339
pubmed: 31649666
Biol Blood Marrow Transplant. 2011 Jan;17(1 Suppl):S101-8
pubmed: 21195297
Aging Cell. 2008 Aug;7(4):506-15
pubmed: 18419796
Nat Cell Biol. 2004 Nov;6(11):1122-8
pubmed: 15467718
Biol Blood Marrow Transplant. 2010 Jul;16(7):985-93
pubmed: 20167280
Diabetes. 2014 Dec;63(12):4314-25
pubmed: 25008184
Blood. 2017 Apr 6;129(14):2021-2032
pubmed: 28096092
Biol Blood Marrow Transplant. 2013 Oct;19(10):1439-45
pubmed: 23845694
FASEB J. 2019 Sep;33(9):9959-9973
pubmed: 31199673
Biol Blood Marrow Transplant. 2013 Jan;19(1):22-7
pubmed: 23041600
BioDrugs. 2021 Jan;35(1):19-33
pubmed: 33201499
Hematology Am Soc Hematol Educ Program. 2019 Dec 6;2019(1):513-521
pubmed: 31808908
Nat Methods. 2012 Jun 28;9(7):676-82
pubmed: 22743772
Haematologica. 2012 Nov;97(11):1674-7
pubmed: 22689672
Biol Blood Marrow Transplant. 2010 Nov;16(11):1504-18
pubmed: 20096359
Bone Marrow Transplant. 2017 Sep;52(9):1317-1325
pubmed: 28650450
N Engl J Med. 1991 Mar 7;324(10):667-74
pubmed: 1994250
Neurogenetics. 2016 Oct;17(4):219-225
pubmed: 27307223
Cell. 1994 Jul 15;78(1):35-43
pubmed: 7518356
Biol Blood Marrow Transplant. 2013 Oct;19(10):1514-7
pubmed: 23871780
J Natl Cancer Inst. 2010 Jun 16;102(12):894-908
pubmed: 20463307
Mol Biol Cell. 2006 Aug;17(8):3423-34
pubmed: 16760425
Haematologica. 2021 Aug 01;106(8):2147-2160
pubmed: 32675225
Mol Cell. 2006 Apr 21;22(2):159-68
pubmed: 16603397
Am J Physiol Heart Circ Physiol. 2011 Sep;301(3):H784-93
pubmed: 21705670
J Cell Mol Med. 2023 May;27(9):1227-1238
pubmed: 37016544
Blood. 2011 Aug 11;118(6):1685-92
pubmed: 21636856
Clin Hematol Int. 2019 Mar 18;1(1):45-51
pubmed: 34595410
Blood. 2011 Apr 21;117(16):4181-9
pubmed: 21258010
J Neurosci. 2008 Oct 8;28(41):10330-8
pubmed: 18842892
Nat Rev Immunol. 2012 May 11;12(6):443-58
pubmed: 22576252
J Invest Dermatol. 1992 Dec;99(6):683-90
pubmed: 1361507
Transplant Cell Ther. 2022 Aug;28(8):489.e1-489.e9
pubmed: 35577323
Curr Biol. 2004 Jul 27;14(14):1296-302
pubmed: 15268862
J Biol Chem. 1995 Jan 13;270(2):815-22
pubmed: 7822316
Pharmacol Res. 2015 Oct;100:170-4
pubmed: 26276086
Nature. 1994 Jun 30;369(6483):756-8
pubmed: 8008069